{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:40:22Z","timestamp":1787002822581,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,2,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Early metastatic spread represents a challenge in fighting small cell lung cancer (SCLC). The molecular mechanisms underlying metastatic dissemination remain unclear in this devastating disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Invasive traits were investigated in 13 SCLC cell lines using 3D-spheroid formation, sprouting assays, co-cultures and a zebrafish xenograft model. Proteomic analysis was performed to unravel metastatic drivers, which were validated by qPCR, growth factor arrays and specific inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 8 cell lines formed spheroids, and half of these displayed invasive sprouting in collagen. The \u2018sprouter\u2019 SCLC cells, which all had a YAP1-dominant subtype, showed increased migration in zebrafish larvae and penetrated endothelial cell monolayers to a higher extent, thereby mimicking intra- and extravasation. Proteomics revealed differences in adhesion properties, oncogenic pathways and receptor tyrosine kinase signalling. Sprouter cells showed higher expression levels of mesenchymal cell state markers. Stimulation with fibroblast growth factor 2 (FGF2) further induced invasive sprouting, while blocking the FGF\/R axis resulted in a significant reduction of sprouting in vitro and in vivo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The FGF\/R axis is a key driver of SCLC metastatic spread in the YAP1-dominant subtype. These data might facilitate the development of potential future therapies targeting FGF\/R signalling to prevent SCLC progression and metastasis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-025-03276-y","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:33:40Z","timestamp":1765611220000},"page":"543-554","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Fibroblast growth factor signals drive the metastatic behavior in small cell lung cancer"],"prefix":"10.1038","volume":"134","author":[{"given":"B\u00fcsra","family":"Ernhofer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Solta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Sinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"Megyesfalvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail J.","family":"Deloria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristiina","family":"Boettiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Glatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilla","family":"Horvath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Sturtzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Wenninger-Weinzierl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Distel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5486-9340","authenticated-orcid":false,"given":"Michael","family":"Grusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Szeitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Rezeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7787-991X","authenticated-orcid":false,"given":"Clemens","family":"Aigner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8799-8624","authenticated-orcid":false,"given":"Balazs","family":"Dome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8742-1737","authenticated-orcid":false,"given":"Karin","family":"Schelch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,13]]},"reference":[{"key":"3276_CR1","doi-asserted-by":"crossref","unstructured":"Megyesfalvi Z, Gay CM, Popper H, Pirker R, Ostoros G, Heeke S, et al. Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions. CA Cancer J Clin. 2023;73:620\u201352.","DOI":"10.3322\/caac.21785"},{"key":"3276_CR2","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202013122","volume":"13","author":"J Ko","year":"2021","unstructured":"Ko J, Winslow MM, Sage J. Mechanisms of small cell lung cancer metastasis. EMBO Mol Med. 2021;13:e13122.","journal-title":"EMBO Mol Med"},{"key":"3276_CR3","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1111\/1759-7714.13854","volume":"12","author":"Z Megyesfalvi","year":"2021","unstructured":"Megyesfalvi Z, Tallosy B, Pipek O, Fillinger J, Lang C, Klikovits T, et al. The landscape of small cell lung cancer metastases: organ specificity and timing. Thorac Cancer. 2021;12:914\u201323.","journal-title":"Thorac Cancer"},{"key":"3276_CR4","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","volume":"19","author":"CM Rudin","year":"2019","unstructured":"Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer. 2019;19:289\u201397.","journal-title":"Nat Rev Cancer"},{"key":"3276_CR5","first-page":"15","volume":"1","author":"CM Gay","year":"2021","unstructured":"Gay CM, Stewart CA, Park EM, Diao L, Groves SM, Heeke S, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021;1:15.","journal-title":"Cancer Cell"},{"key":"3276_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1060","volume":"12","author":"B Szeitz","year":"2022","unstructured":"Szeitz B, Megyesfalvi Z, Woldmar N, Valk\u00f3 Z, Schwendenwein A, B\u00e1r\u00e1ny N, et al. In-depth proteomic analysis reveals unique subtype-specific signatures in human small-cell lung cancer. Clin Transl Med. 2022;12:e1060.","journal-title":"Clin Transl Med"},{"key":"3276_CR7","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nrm3758","volume":"15","author":"S Lamouille","year":"2014","unstructured":"Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial\u2013mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178\u201396.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3276_CR8","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/1878-0261.13367","volume":"18","author":"K Schelch","year":"2024","unstructured":"Schelch K, Eder S, Zitta B, Phimmachanh M, Johnson TG, Emminger D, et al. YB-1 regulates mesothelioma cell migration via Snail but not EGFR, MMP1, EPHA5 or PARK2. Mol Oncol. 2024;18:815\u201331.","journal-title":"Mol Oncol"},{"key":"3276_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13046-022-02582-0","volume":"42","author":"A Ries","year":"2023","unstructured":"Ries A, Flehberger D, Slany A, Pirker C, Mader JC, Mohr T, et al. Mesothelioma-associated fibroblasts enhance proliferation and migration of pleural mesothelioma cells via c-Met\/PI3K and WNT signaling but do not protect against cisplatin. J Exp Clin Cancer Res. 2023;42:27.","journal-title":"J Exp Clin Cancer Res"},{"key":"3276_CR10","doi-asserted-by":"crossref","unstructured":"Schelch K, Wagner C, Hager S, Pirker C, Siess K, Lang E et al. FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase\/MMP1 signal. Carcinogenesis. 2018;39:534\u201345.","DOI":"10.1093\/carcin\/bgy018"},{"key":"3276_CR11","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676\u201382.","journal-title":"Nat Methods"},{"key":"3276_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhazmat.2025.139129","volume":"495","author":"B Ernhofer","year":"2025","unstructured":"Ernhofer B, Spittler A, Ferk F, Mi\u0161\u00edk M, Zylka MM, Glatt L, et al. Small particles, big problems: polystyrene nanoparticles induce DNA damage, oxidative stress, migration, and mitogenic pathways predominantly in non-malignant lung cells. J Hazard Mater. 2025;495:139129.","journal-title":"J Hazard Mater"},{"key":"3276_CR13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/aja.1002030302","volume":"203","author":"CB Kimmel","year":"1995","unstructured":"Kimmel CB, Ballard WW, Kimmel SR, Ullmann B, Schilling TF. Stages of embryonic development of the zebrafish. Dev Dyn. 1995;203:253\u2013310.","journal-title":"Dev Dyn"},{"key":"3276_CR14","unstructured":"Westerfield M. The zebrafish book. A guide for the laboratory use of zebrafish (Danio rerio). Eugene: University of Oregon Press; 2000."},{"key":"3276_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.216028","volume":"554","author":"S Grissenberger","year":"2023","unstructured":"Grissenberger S, Sturtzel C, Wenninger-Weinzierl A, Radic-Sarikas B, Scheuringer E, Bierbaumer L, et al. High-content drug screening in zebrafish xenografts reveals high efficacy of dual MCL-1\/BCL-XL inhibition against Ewing sarcoma. Cancer Lett. 2023;554:216028.","journal-title":"Cancer Lett"},{"key":"3276_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00386-9","volume":"7","author":"C Sturtzel","year":"2023","unstructured":"Sturtzel C, Grissenberger S, Bozatzi P, Scheuringer E, Wenninger-Weinzierl A, Zajec Z, et al. Refined high-content imaging-based phenotypic drug screening in zebrafish xenografts. npj Precis Oncol. 2023;7:44.","journal-title":"npj Precis Oncol"},{"key":"3276_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa M. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28:27\u201330. Jan.","journal-title":"Nucleic Acids Res"},{"key":"3276_CR18","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3276_CR19","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ng1180","volume":"34","author":"VK Mootha","year":"2003","unstructured":"Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al. PGC-1\u03b1-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34:267\u201373.","journal-title":"Nat Genet"},{"key":"3276_CR20","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1158\/1078-0432.CCR-23-2360","volume":"30","author":"J Ng","year":"2024","unstructured":"Ng J, Cai L, Girard L, Prall OWJ, Rajan N, Khoo C, et al. Molecular and pathologic characterization of YAP1-expressing small cell lung cancer cell lines leads to reclassification as smarca4-deficient malignancies. Clin Cancer Res. 2024;30:1846\u201358.","journal-title":"Clin Cancer Res"},{"key":"3276_CR21","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/path.5922","volume":"257","author":"Z Megyesfalvi","year":"2022","unstructured":"Megyesfalvi Z, Barany N, Lantos A, Valko Z, Pipek O, Lang C, et al. Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study. J Pathol. 2022;257:674\u201386.","journal-title":"J Pathol"},{"key":"3276_CR22","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1002\/cncr.24314","volume":"115","author":"NR Foster","year":"2009","unstructured":"Foster NR, Mandrekar SJ, Schild SE, Nelson GD, Rowland KM, Deming RL, et al. Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of North Central Cancer Treatment Group trials. Cancer. 2009;115:2721\u201331.","journal-title":"Cancer"},{"key":"3276_CR23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.21037\/tlcr.2018.01.15","volume":"7","author":"YT Shue","year":"2018","unstructured":"Shue YT, Lim JS, Sage J. Tumor heterogeneity in small cell lung cancer defined and investigated in pre-clinical mouse models. Transl Lung Cancer Res. 2018;7:21\u201331.","journal-title":"Transl Lung Cancer Res"},{"key":"3276_CR24","doi-asserted-by":"publisher","first-page":"73745","DOI":"10.18632\/oncotarget.20572","volume":"8","author":"K McColl","year":"2017","unstructured":"McColl K, Wildey G, Sakre N, Lipka MB, Behtaj M, Kresak A, et al. Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer. Oncotarget. 2017;8:73745\u201356.","journal-title":"Oncotarget"},{"key":"3276_CR25","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ccr.2010.12.021","volume":"19","author":"J Calbo","year":"2011","unstructured":"Calbo J, van Montfort E, Proost N, van Drunen E, Beverloo HB, Meuwissen R, et al. A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer. Cancer Cell. 2011;19:244\u201356. Feb.","journal-title":"Cancer Cell"},{"key":"3276_CR26","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1016\/j.celrep.2019.05.057","volume":"27","author":"F B\u00f6ttger","year":"2019","unstructured":"B\u00f6ttger F, Semenova EA, Song JY, Ferone G, van der Vliet J, Cozijnsen M, et al. Tumor heterogeneity underlies differential cisplatin sensitivity in mouse models of small-cell lung cancer. Cell Rep. 2019;27:3345\u20133358.e4. Jun.","journal-title":"Cell Rep"},{"key":"3276_CR27","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.cllc.2016.05.015","volume":"17","author":"M Pore","year":"2016","unstructured":"Pore M, Meijer C, de Bock GH, Boersma-van Ek W, Terstappen LWMM, Groen HJM, et al. Cancer stem cells, epithelial to mesenchymal markers, and circulating tumor cells in small cell lung cancer. Clin Lung Cancer. 2016;17:535\u201342.","journal-title":"Clin Lung Cancer"},{"key":"3276_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.370","volume":"4","author":"C Deng","year":"2023","unstructured":"Deng C, Wang Y, Fu F, Li D, Zheng Q, Jin Y, et al. Tumor-derived Vimentin as a novel biomarker for distinct subtypes predicting adjuvant chemotherapy resistance and T-cell-inflamed phenotype in small cell lung cancer. MedComm. 2023;4:e370.","journal-title":"MedComm"},{"key":"3276_CR29","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.bbamcr.2006.11.017","volume":"1773","author":"Y Wu","year":"2007","unstructured":"Wu Y, Zhang X, Salmon M, Lin X, Zehner ZE. TGFbeta1 regulation of vimentin gene expression during differentiation of the C2C12 skeletal myogenic cell line requires Smads, AP-1 and Sp1 family members. Biochim Biophys Acta. 2007;1773:427\u201339.","journal-title":"Biochim Biophys Acta"},{"key":"3276_CR30","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/cr.2011.144","volume":"22","author":"Q Qin","year":"2012","unstructured":"Qin Q, Xu Y, He T, Qin C, Xu J. Normal and disease-related biological functions of Twist1 and underlying molecular mechanisms. Cell Res. 2012;22:90\u2013106.","journal-title":"Cell Res"},{"key":"3276_CR31","doi-asserted-by":"crossref","unstructured":"Sato T, Kaneda A, Tsuji S, Isagawa T, Yamamoto S, Fujita T, et al. PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer. Sci Rep. 2013;3:1911.","DOI":"10.1038\/srep01911"},{"key":"3276_CR32","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1517\/14728222.2011.566217","volume":"15","author":"C Heinzle","year":"2011","unstructured":"Heinzle C, Sutterl\u00fcty H, Grusch M, Grasl-Kraupp B, Berger W, Marian B. Targeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapy. Expert Opin Ther Targets. 2011;15:829\u201346.","journal-title":"Expert Opin Ther Targets"},{"key":"3276_CR33","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jtho.2015.08.003","volume":"11","author":"A Desai","year":"2016","unstructured":"Desai A, Adjei AA. FGFR signaling as a target for lung cancer therapy. J Thorac Oncol. 2016;11:9\u201320.","journal-title":"J Thorac Oncol"},{"key":"3276_CR34","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1164\/rccm.201404-0658OC","volume":"190","author":"K Schelch","year":"2014","unstructured":"Schelch K, Hoda MA, Klikovits T, M\u00fcnzker J, Ghanim B, Wagner C, et al. Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy. Am J Respir Crit Care Med. 2014;190:763\u201372.","journal-title":"Am J Respir Crit Care Med"},{"key":"3276_CR35","doi-asserted-by":"publisher","first-page":"5051","DOI":"10.1158\/0008-5472.CAN-20-1453","volume":"80","author":"KB Kim","year":"2020","unstructured":"Kim KB, Kim Y, Rivard CJ, Kim DW, Park KS. FGFR1 is critical for RBL2 loss-driven tumor development and requires PLCG1 activation for continued growth of small cell lung cancer. Cancer Res. 2020;80:5051\u201362.","journal-title":"Cancer Res"},{"key":"3276_CR36","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1038\/bjc.2014.229","volume":"110","author":"N Cihoric","year":"2014","unstructured":"Cihoric N, Savic S, Schneider S, Ackermann I, Bichsel-Naef M, Schmid RA, et al. Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer. Br J Cancer. 2014;110:2914\u201322.","journal-title":"Br J Cancer"},{"key":"3276_CR37","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/modpathol.2013.141","volume":"27","author":"AM Schultheis","year":"2014","unstructured":"Schultheis AM, Bos M, Schmitz K, Wilsberg L, Binot E, Wolf J, et al. Fibroblast growth factor receptor 1 (FGFR1) amplification is a potential therapeutic target in small-cell lung cancer. Mod Pathol. 2014;27:214\u201321.","journal-title":"Mod Pathol"},{"key":"3276_CR38","doi-asserted-by":"publisher","first-page":"5340","DOI":"10.1038\/s41388-018-0311-3","volume":"37","author":"K Wang","year":"2018","unstructured":"Wang K, Ji W, Yu Y, Li Z, Niu X, Xia W, et al. FGFR1-ERK1\/2-SOX2 axis promotes cell proliferation, epithelial\u2013mesenchymal transition, and metastasis in FGFR1-amplified lung cancer. Oncogene. 2018;37:5340\u201354.","journal-title":"Oncogene"},{"key":"3276_CR39","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1097\/JTO.0000000000000562","volume":"10","author":"L Zhang","year":"2015","unstructured":"Zhang L, Yu H, Badzio A, Boyle TA, Schildhaus HU, Lu X, et al. Fibroblast growth factor receptor 1 and related ligands in small-cell lung cancer. J Thorac Oncol. 2015;10:1083\u201390.","journal-title":"J Thorac Oncol"},{"key":"3276_CR40","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1101\/gad.262998.115","volume":"29","author":"KM chul","year":"2015","unstructured":"chul KM, Proost N, Song JY, Sutherland KD, Zevenhoven J, Berns A. Paracrine signaling between tumor subclones of mouse SCLC: a critical role of ETS transcription factor Pea3 in facilitating metastasis. Genes Dev. 2015;29:1587\u201392.","journal-title":"Genes Dev"},{"key":"3276_CR41","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.cllc.2022.05.012","volume":"23","author":"F Cucchiara","year":"2022","unstructured":"Cucchiara F, Petrini I, Passaro A, Attili I, Crucitta S, Pardini E, et al. Gene network analysis defines a subgroup of small cell lung cancer patients with short survival. Clin Lung Cancer. 2022;23:510\u201321.","journal-title":"Clin Lung Cancer"},{"key":"3276_CR42","doi-asserted-by":"publisher","first-page":"3916","DOI":"10.1158\/0008-5472.CAN-20-4048","volume":"81","author":"K Ishioka","year":"2021","unstructured":"Ishioka K, Yasuda H, Hamamoto J, Terai H, Emoto K, Kim TJ, et al. Upregulation of FGF9 in lung adenocarcinoma transdifferentiation to small cell lung cancer. Cancer Res. 2021;81:3916\u201329.","journal-title":"Cancer Res"},{"key":"3276_CR43","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41388-022-02558-6","volume":"42","author":"DW Shia","year":"2023","unstructured":"Shia DW, Choi W, Vijayaraj P, Vuong V, Sandlin JM, Lu MM, et al. Targeting PEA3 transcription factors to mitigate small cell lung cancer progression. Oncogene. 2023;42:434\u201348.","journal-title":"Oncogene"},{"key":"3276_CR44","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.ejca.2014.11.015","volume":"51","author":"S Novello","year":"2015","unstructured":"Novello S, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, et al. Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer. Eur J Cancer. 2015;51:317\u201326.","journal-title":"Eur J Cancer"},{"key":"3276_CR45","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s40265-014-0335-0","volume":"75","author":"PL McCormack","year":"2015","unstructured":"McCormack PL. Nintedanib: first global approval. Drugs. 2015;75:129\u201339.","journal-title":"Drugs"},{"key":"3276_CR46","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1513\/AnnalsATS.202311-941OC","volume":"21","author":"S Ikeda","year":"2024","unstructured":"Ikeda S, Ogura T, Kato T, Kenmotsu H, Agemi Y, Tokito T, et al. Nintedanib plus chemotherapy for small cell lung cancer with comorbid idiopathic pulmonary fibrosis. Ann Am Thorac Soc. 2024;21:635\u201343.","journal-title":"Ann Am Thorac Soc"},{"key":"3276_CR47","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1817323","volume":"381","author":"Y Loriot","year":"2019","unstructured":"Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381:338\u201348.","journal-title":"N Engl J Med"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03276-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03276-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03276-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T12:03:16Z","timestamp":1769774596000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03276-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,13]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,2,20]]}},"alternative-id":["3276"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-03276-y","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,13]]},"assertion":[{"value":"5 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"For the use of international cell lines, no ethics approval was required. Xenografts in zebrafish larvae are not considered \u2018classical\u2019 animal studies using live vertebrates and, therefore, no ethics was needed for these works either. Xenotransplantation license: GZ:333989-2020-4.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"ETHICS APPROVAL AND CONSENT TO PARTICIPATE"}}]}}